Search results for: Multi-Indication Medicines
Filter search results
New research reveals, in carers’ own words, the multidimensional burden of caring for leukemia patients
20 November 2025
A first-of-its-kind multinational qualitative survey of informal carers brings to life the multi-dimensional burden of providing informal care to someone living with acute leukemia (AL). 58% of informal carers experienced…
Spotlight on OHE: Beyond QALYs, Managed Entry Agreements, Business Models for Antibiotics, and the UK Market for Medicines.
12 April 2016
…topic of the economics of the market for medicines. The first half of the lecture included an overview of the global challenges facing medicines manufacturers, discussion of the ‘supply side’…
Brand Names in Prescribing
1 September 1976
…been shown to be due to the use of different medicines containing the same drug. It is imperative in the interest of patients that any new medicines introduced to the…
Drivers of the Growth in Medicines Expenditure
1 October 1997
Increases in expenditure on medicines, above the level of increases in health care expenditure generally, are a feature of all Western health systems, including the UK’s. This paper examines the…
Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions
1 January 2020
…ethical and economic challenges faced by medicines for ultra-rare conditions, with particular reference… In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised…
A Market-based International Reference Price Index: Solution or Contradiction?
13 September 2019
…Their governments have a central role in medicines purchase, in contrast to U.S. reliance on private markets. The Trump Administration has proposed using an International Pricing Index (IPI), which seeks…
Value Based Pricing in the UK
7 September 2010
…therapies, particularly new medicines. Health technology assessment, he believes, is an important tool, but only if used appropriately and within its limits. In the UK, prices for medicines are guided…
Why President Trump’s generic drug tariffs are unlikely to fix America’s supply problem
13 August 2026
…needed to make medicines subject to “ransom” by exporters. Similarly, there is no indication as to whether the tariffs will apply to biosimilars (highly similar versions of biologic medicines). This…
Using MCDA to Assess the Value of Treatments for Rare Diseases
5 December 2013
…(OHE) and its collaborators, medicines for rare disease may be effectively valued using an innovative approach — multi-criteria decision analysis (MCDA) — that can include all relevant stakeholders, including patients’…